drugset / Trial / NCT00697229
Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety, immunogenicity and reactogenicity of MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following two different schedules: 0, 2 months and 0, 6 months
Timeline
- Start
- 1992-09
- Primary completion
- 1996-05
- Completion
- 1998-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine | Vaccine | — | Intramuscular |